Isowater® is pleased to see this precedent setting FDA approval in place for Austedo by Teva. It has had the developmental name of SD-809. As it is for the treatment… Continue reading →
News
Deuterium use in Life Science Applications Highlighted in Specialty Chemicals Magazine
Deuterium oxide is being used in key pharmaceutical applications as reported by Dr. Sarah Harding of Specialty Chemicals Magazine in their Pharmaceuticals section of the April 2017 magazine. With a… Continue reading →
The Chemical and Engineering News – Deuterated Drugs & Isowater’s® Role
The Chemical and Engineering News (C&EN), a publication of the American Chemical Society is a leading source of technical information for the Life Sciences industry. An article published in early… Continue reading →
The Economist Magazine Reports on Deuterated Pharmaceuticals
The excitement and growth potential of deuterated pharmaceuticals is going main-stream as reported in the Economist magazine in their Medical Chemistry section (see link below). With the emphasis being “Drugs… Continue reading →
Isowater® Completes $3.2M Development Program
-Technology to Solve Coming Deuterium Oxide Supply Crunch- Collingwood, Ontario August 17, 2015, Isowater® Corporation is pleased to announce that it has completed a $3.2 million multiyear development project to… Continue reading →
Isowater® Strengthens Business Development and Marketing Team
Toronto, Ontario March 12, 2014, Isowater® Corporation (Isowater®), a reliable supplier of deuterium oxide (heavy water), is pleased to announce that Dr. Joseph Porwoll and Ms. Wanda Cutler have joined… Continue reading →
Isowater® and AECL Sign Deuterium Oxide (Heavy Water) Marketing and Collaboration Agreement
Ottawa, Ontario February 27, 2014, Isowater® Corporation (Isowater®) and Atomic Energy of Canada Limited (AECL) are pleased to announce the signing of an agreement to advance deuterium oxide (heavy water)… Continue reading →
Another Major Investment in Deuterium Technology for Pharmaceuticals
First Auspex Pharmaceuticals announces its IPO priced at $12.00 per share, and now Concert Pharmaceuticals announces its IPO at $14.00 per share. Auspex and Concert are both working on developing… Continue reading →
Major Investment in Technology for Pharmaceuticals
Auspex Pharmaceuticals Inc has raised $35 million which will advance the clinical trials of its deuterium substituted drug SD-809 designed for the treatment of chorea associated with Huntington’s disease. In… Continue reading →
Seasons Greetings from Isowater®
Possible new use for deuterium oxide on December 24th? Happy Holidays!